FRESENIUS KABI

Succinylcholine
Chloride Injection, USP

100 mg per 5 mL and 200 mg per 10 mL Simplist® ready-to-administer prefilled syringes available from Fresenius Kabi.

- Manufacturer prepared
- 18-month shelf life
- RFID-enabled
- 10 syringes per carton

Succinylcholine Chloride Injection, USP

IMPORTANT SAFETY INFORMATION:

WARNING: VENTRICULAR DYSRHYTHMIAS, CARDIAC ARREST, AND DEATH FROM HYPERKALEMIC RHABDOMYOLYSIS IN PEDIATRIC PATIENTS

- **Acute rhabdomyolysis with hyperkalemia followed by ventricular dysrhythmias, cardiac arrest, and death has occurred after the administration of succinylcholine to apparently healthy pediatric patients who were subsequently found to have undiagnosed skeletal muscle myopathy, most frequently Duchenne muscular dystrophy.**
- **When a healthy appearing pediatric patient develops cardiac arrest within minutes after administration of Succinylcholine Chloride Injection, not felt to be due to inadequate ventilation, oxygenation or anesthetic overdose, immediate treatment for hyperkalemia should be instituted. In the presence of signs of malignant hyperthermia, appropriate treatment should be instituted concurrently.**
- **Reserve the use of Succinylcholine Chloride Injection in pediatric patients for emergency intubation or instances where immediate securing of the airway is necessary, e.g., laryngospasm, difficult airway, full stomach, or for intramuscular use when a suitable vein is inaccessible.**

CONTRAINDICATIONS

- In patients with skeletal muscle myopathies
- In patients with known hypersensitivity to succinylcholine
- After the acute phase of injury following major burns, multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron injury
- In patients with a personal or familial history or suspected genetic susceptibility to malignant hyperthermia

WARNINGS AND PRECAUTIONS

- Anaphylaxis: Severe anaphylactic reactions to neuromuscular blocking agents, including succinylcholine, have been reported. Some cases have been life-threatening and fatal. Take necessary precautions, such as the immediate availability of appropriate emergency treatment.
- Risk of Death due Medication Errors: Unintended administration of Succinylcholine Chloride Injection may result in paralysis, respiratory arrest and death. Confirm proper selection of intended product and avoid confusion with other injectable solutions that are present in critical care and other clinical settings.
- Hyperkalemia: Succinylcholine Chloride Injection may induce serious cardiac arrhythmias or cardiac arrest due to hyperkalemia.
- Malignant Hyperthermia: Malignant hyperthermia may occur, especially in individuals with known or suspected susceptibility based on genetic factors or family history. Discontinue triggering agents, administer intravenous dantrolene sodium, and apply supportive therapies.
- Bradycardia: Intravenous bolus administration may result in profound bradycardia or, rarely asystole. The incidence is higher following a second dose of succinylcholine. Pretreatment with anticholinergic agents (e.g. atropine) may reduce the occurrence of bradyarrhythmias.

ADVERSE REACTIONS

Adverse reactions reported with succinylcholine are cardiac arrest, malignant hyperthermia, arrhythmias, bradycardia, tachycardia, hypertension, hypotension, hyperkalemia, prolonged respiratory depression or apnea.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC, at 1-800-551-7176 option 5, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Drugs that May Enhance the Neuromuscular Blocking Action of Succinylcholine: promazine, oxytocin, aprotinin, certain non-penicillin antibiotics, quinidine, β-adrenergic blockers, procainamide, lidocaine, trimethaphan, lithium carbonate, magnesium salts, quinine, chloroquine, isoflurane, desflurane, metoclopramide, terbutaline, and drugs that reduce plasma cholinesterase activity.

INDICATIONS AND USAGE

Succinylcholine Chloride Injection is a depolarizing neuromuscular blocker indicated in adults and pediatric patients:

- As an adjunct to general anesthesia
- To facilitate tracheal intubation
- To provide skeletal muscle relaxation during surgery or mechanical ventilation.

This Important Safety Information does not include all the information needed to use Succinylcholine Chloride Injection, USP safely and effectively. Please see the full prescribing information, including BOXED WARNING, for Succinylcholine Chloride Injection, USP 100 mg per 5 mL and 200 mg per 10 mL.

Simplist®

Succinylcholine
Chloride Injection, USP

Strength	100 mg per 5 mL	200 mg per 10 mL
Concentration	20 mg per mL	20 mg per mL
Unit of sale NDC	65219-274-05	65219-276-10
Fill volume	5 mL	10 mL
Unit of sale bar code	(01)20365219274050	(01)20365219276108
Pack size	10 per Carton	10 per Carton
Secondary packaging	Flow wrap	Flow wrap
Secondary packaging dimensions	9.843" x 1.929" x 1.063"	9.567" x 1.929" x 1.063"
Carton dimensions	5.748" x 3.031" x 8.11"	5.748" x 3.031" x 10.079"
Wholesale numbers		
Cardinal	6041347	6041354
Cencora	10301624	10301577
McKesson	3045846	3045853
Morris & Dickson	756114	756155

To place an order, contact your Sales Representative or call Customer Service at 1.888.386.1300 | www.simplist-us.com

FRESENIUS KABI

Fresenius Kabi USA, LLC
Three Corporate Drive
Lake Zurich, IL 60047
Phone: 1.888.386.1300
www.fresenius-kabi.com/us

Please see the full prescribing information, including BOXED WARNING, for Succinylcholine Chloride Injection, USP 100 mg per 5 mL and 200 mg per 10 mL.

© 2025 Fresenius Kabi USA, LLC. All Rights Reserved. 6154-SCI-02-06/25 v1.0